Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092798984> ?p ?o ?g. }
- W3092798984 endingPage "700" @default.
- W3092798984 startingPage "688" @default.
- W3092798984 abstract "Purpose To evaluate patient- and treatment-related risk factors associated with incidence and persistence of late diarrhea after radiochemotherapy and image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Materials and Methods Of 1416 patients from the EMBRACE I study, 1199 were prospectively evaluated using physician-reported (Common Terminology Criteria for Adverse Events version 3 [CTCAEv3]) assessment for diarrhea; median follow-up 48 months. Patient-reported outcome (EORTC) was available in 900 patients. Incidence of CTCAE G≥2, G≥3, and EORTC “very much” diarrhea was analyzed with Cox proportional hazards regression. Binary logistic regression was used for analysis of persistent G≥1 and EORTC “quite a bit” - “very much” (≥“quite a bit”) diarrhea, defined if present in at least half of all follow-ups. Results Crude incidences of G≥2 and G≥3 diarrhea were 8.3% and 1.5%, respectively, and 8% of patients reported “very much” diarrhea. Persistent G≥1 and ≥“quite a bit” diarrhea was present in 16% and 7%, respectively. Patient-related risk factors were baseline diarrhea, smoking, and diabetes with hazard ratios of 1.4 to 7.3. Treatment-related risk factors included prescribed dose, V43 Gy, V57 Gy (lymph node boost), and para-aortic irradiation for external beam radiation therapy (EBRT). G≥2 diarrhea at 3 years increased from 9.5% to 19.9% with prescribed dose 45 Gy versus 50 Gy, 8.7% to 14.0% with V43 Gy <2500 cm3 versus >3000 cm3 and 9.4% to 19.0% with V57 Gy <165 cm3 versus ≥165 cm3. Brachytherapy-related bowel and rectum D2cm3 were also associated with diarrhea. Conclusion Dose and volume effects have been established for late diarrhea after radiochemotherapy and IGABT in both CTCAE and EORTC reporting. The risk of diarrhea was lower with a pelvic EBRT prescription of 45 Gy, and higher with larger lymph node boosts volumes (ie, ≥165 cm3). The importance of EBRT volumes as determinants of late toxicity underline the need for continuous quality assurance of target contouring, dose planning, and conformity. The findings of brachytherapy dosimetric factors related to the intestines may become more important with highly conformal EBRT. To evaluate patient- and treatment-related risk factors associated with incidence and persistence of late diarrhea after radiochemotherapy and image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Of 1416 patients from the EMBRACE I study, 1199 were prospectively evaluated using physician-reported (Common Terminology Criteria for Adverse Events version 3 [CTCAEv3]) assessment for diarrhea; median follow-up 48 months. Patient-reported outcome (EORTC) was available in 900 patients. Incidence of CTCAE G≥2, G≥3, and EORTC “very much” diarrhea was analyzed with Cox proportional hazards regression. Binary logistic regression was used for analysis of persistent G≥1 and EORTC “quite a bit” - “very much” (≥“quite a bit”) diarrhea, defined if present in at least half of all follow-ups. Crude incidences of G≥2 and G≥3 diarrhea were 8.3% and 1.5%, respectively, and 8% of patients reported “very much” diarrhea. Persistent G≥1 and ≥“quite a bit” diarrhea was present in 16% and 7%, respectively. Patient-related risk factors were baseline diarrhea, smoking, and diabetes with hazard ratios of 1.4 to 7.3. Treatment-related risk factors included prescribed dose, V43 Gy, V57 Gy (lymph node boost), and para-aortic irradiation for external beam radiation therapy (EBRT). G≥2 diarrhea at 3 years increased from 9.5% to 19.9% with prescribed dose 45 Gy versus 50 Gy, 8.7% to 14.0% with V43 Gy <2500 cm3 versus >3000 cm3 and 9.4% to 19.0% with V57 Gy <165 cm3 versus ≥165 cm3. Brachytherapy-related bowel and rectum D2cm3 were also associated with diarrhea. Dose and volume effects have been established for late diarrhea after radiochemotherapy and IGABT in both CTCAE and EORTC reporting. The risk of diarrhea was lower with a pelvic EBRT prescription of 45 Gy, and higher with larger lymph node boosts volumes (ie, ≥165 cm3). The importance of EBRT volumes as determinants of late toxicity underline the need for continuous quality assurance of target contouring, dose planning, and conformity. The findings of brachytherapy dosimetric factors related to the intestines may become more important with highly conformal EBRT." @default.
- W3092798984 created "2020-10-22" @default.
- W3092798984 creator A5007180426 @default.
- W3092798984 creator A5008211705 @default.
- W3092798984 creator A5009197248 @default.
- W3092798984 creator A5010078716 @default.
- W3092798984 creator A5012456198 @default.
- W3092798984 creator A5015936442 @default.
- W3092798984 creator A5018059259 @default.
- W3092798984 creator A5020453607 @default.
- W3092798984 creator A5022658116 @default.
- W3092798984 creator A5023906981 @default.
- W3092798984 creator A5042729624 @default.
- W3092798984 creator A5051264147 @default.
- W3092798984 creator A5051996971 @default.
- W3092798984 creator A5052993599 @default.
- W3092798984 creator A5055283037 @default.
- W3092798984 creator A5058848857 @default.
- W3092798984 creator A5059230022 @default.
- W3092798984 creator A5065204901 @default.
- W3092798984 creator A5067216360 @default.
- W3092798984 creator A5071171991 @default.
- W3092798984 creator A5072760427 @default.
- W3092798984 creator A5073239916 @default.
- W3092798984 creator A5077820862 @default.
- W3092798984 creator A5085262681 @default.
- W3092798984 date "2021-03-01" @default.
- W3092798984 modified "2023-10-14" @default.
- W3092798984 title "Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study" @default.
- W3092798984 cites W1566325063 @default.
- W3092798984 cites W1968626722 @default.
- W3092798984 cites W1999267929 @default.
- W3092798984 cites W2006747078 @default.
- W3092798984 cites W2018266005 @default.
- W3092798984 cites W2026511819 @default.
- W3092798984 cites W2041815133 @default.
- W3092798984 cites W2042262831 @default.
- W3092798984 cites W2064754413 @default.
- W3092798984 cites W2077617763 @default.
- W3092798984 cites W2081977840 @default.
- W3092798984 cites W2097115909 @default.
- W3092798984 cites W2116957079 @default.
- W3092798984 cites W2118943250 @default.
- W3092798984 cites W2122859516 @default.
- W3092798984 cites W2128683940 @default.
- W3092798984 cites W2138612212 @default.
- W3092798984 cites W2149426916 @default.
- W3092798984 cites W2155717089 @default.
- W3092798984 cites W2156910950 @default.
- W3092798984 cites W2159230013 @default.
- W3092798984 cites W2167571044 @default.
- W3092798984 cites W2222645822 @default.
- W3092798984 cites W2345268804 @default.
- W3092798984 cites W2385263471 @default.
- W3092798984 cites W2472531047 @default.
- W3092798984 cites W2587415549 @default.
- W3092798984 cites W2602377655 @default.
- W3092798984 cites W2751309234 @default.
- W3092798984 cites W2752709125 @default.
- W3092798984 cites W2783123637 @default.
- W3092798984 cites W2784443212 @default.
- W3092798984 cites W2795916298 @default.
- W3092798984 cites W2804217778 @default.
- W3092798984 cites W2805434219 @default.
- W3092798984 cites W2835635281 @default.
- W3092798984 cites W2891383419 @default.
- W3092798984 cites W2905770829 @default.
- W3092798984 cites W2909738547 @default.
- W3092798984 cites W2919780169 @default.
- W3092798984 cites W2924331584 @default.
- W3092798984 cites W2942946986 @default.
- W3092798984 cites W2953862252 @default.
- W3092798984 cites W2966648742 @default.
- W3092798984 cites W2981593013 @default.
- W3092798984 cites W3003769853 @default.
- W3092798984 cites W4255591201 @default.
- W3092798984 doi "https://doi.org/10.1016/j.ijrobp.2020.10.006" @default.
- W3092798984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33068689" @default.
- W3092798984 hasPublicationYear "2021" @default.
- W3092798984 type Work @default.
- W3092798984 sameAs 3092798984 @default.
- W3092798984 citedByCount "27" @default.
- W3092798984 countsByYear W30927989842021 @default.
- W3092798984 countsByYear W30927989842022 @default.
- W3092798984 countsByYear W30927989842023 @default.
- W3092798984 crossrefType "journal-article" @default.
- W3092798984 hasAuthorship W3092798984A5007180426 @default.
- W3092798984 hasAuthorship W3092798984A5008211705 @default.
- W3092798984 hasAuthorship W3092798984A5009197248 @default.
- W3092798984 hasAuthorship W3092798984A5010078716 @default.
- W3092798984 hasAuthorship W3092798984A5012456198 @default.
- W3092798984 hasAuthorship W3092798984A5015936442 @default.
- W3092798984 hasAuthorship W3092798984A5018059259 @default.
- W3092798984 hasAuthorship W3092798984A5020453607 @default.
- W3092798984 hasAuthorship W3092798984A5022658116 @default.
- W3092798984 hasAuthorship W3092798984A5023906981 @default.
- W3092798984 hasAuthorship W3092798984A5042729624 @default.
- W3092798984 hasAuthorship W3092798984A5051264147 @default.